Key clinical point: Quality of life differences between salvage autologous stem cell transplant (ASCT) and nontransplant consolidation are small in multiple myeloma patients.
Major finding: Global health status scores were lower 100 days after salvage ASCT versus nontransplant consolidation, but not thereafter.
Study details: Secondary quality of life analysis with 171 patients in the Myeloma X trial.
Disclosures: The study was supported by Cancer Research UK, Janssen-Cilag, and Chugai Pharma UK. Dr. Ahmedzai reported honoraria, consulting, research funding, and travel fees from various companies, not including the study sponsors.
Ahmedzai SH et al. J Clin Oncol. 2019 Apr 10. doi: 10.1200/JCO.18.01006.